Published in Women's Health Weekly, March 23rd, 2006
According to recent research from the United States, "We analyzed the development of nevirapine (NVP) resistance in human immunodeficiency virus type 1 (HIV-1)-infected Malawian infants who received regimens containing single dose NVP (SD-NVP) for the prevention of mother-to-child transmission (MTCT) of HIV-1.
"All infants received SD-NVP, and some randomly received zidovudine (ZDV) as well. Mothers did or did not receive SD-NVP on the basis of when they arrived at the hospital for delivery."
"In infants 6-8 weeks...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly